@angelus512 thanks for the summary - like many I haven't yet had the chance to listen to the call.
I remain puzzled why the echocardiographic assessments of the myocardial size and function by transthoracic echocardiography results weren't reported as NIH will have them (they were first on the list of secondary endpoints whereas hospitalisations were down the bottom of the list and GI bleeding didn't feature at all) and obviously shared a lot of other detailed results with MSB.
Also missing are the histopathological assessments of myocardial tissue. Both of these parameters are critical for the market to assess the impact on the CHF Phase 3 - I am worried that MSB is touting the NIH results as supporting a positive outcome in the Phase 3 while failing to share these critical data with the market.
I can maybe understand the missing 6-Minute Walk Test because that was only carried out on weaned patients according to the CT protocol, but overall the lack of disclosure is a concern.
MSB Price at posting:
$1.48 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)